Abstract

A REVIEW ON ADVANCEMENT OF RIFAMPICIN INTO LIPOSOMAL FORMULATION

Nithin A. Mathew*, Shwetha, Bhaskar Pandey, S. MD Sameer Qureshi and Tushar Vashisth

.

Abstract

By improving the formulation, an extended release of rifampicin will be achieved. Liposomes have been a capable drug delivery system with flexible drug vesicles. Compared to other drug deliveries they have rapid on-site action, slow or controlled release, protection of drug from degradation. In this review liposomal formulation of rifampicin can obtain higher bioavailability than the traditional one. It is a BCS class 2 drug with lower solubility profile. By advancing this to nanoformulation this can increase the solubility by slowly liberating the drug in the intestine. It can slowly reduce growth or kills the grampositive bacteria that causes tuberculosis (TB) by releasing the drug into the systemic circulation. It has an antibacterial activity. It is normally given with other drugs or combined with isoniazid, ethambutol. It may increase the side effects or toxicity. Patients administering with this drug can cause more adverse effects like stains in body, anorexia. So due to multiple drugs and its dosage can cause effects. To reduce this liposomal formulation of less dosage can reduce the side effects. To overcome all this toxicity and dosage of drug nano-formulation of rifampicin is brought to an idea. Improved drug formulation can be administered daily with minimum side effects. This review is to obtain an idea for the drug to be effective and give maximum bioavailability inside the body.

Keywords: liposomes, Bioavailability, Nano-formulation.